Table 5 Comparison of the primary and secondary outcomes for patients who received the REACH-HF intervention at the Beacon Sites between June 2019 and June 2020 and those recruited into the REACH-HF trial
Measure | Pre | Post | Effect size Hedges’ g (95% CI) | ||||
|---|---|---|---|---|---|---|---|
N | Mean | SD | N | Mean | SD | ||
MLHFQ | |||||||
Beacon Sites | 50 | 36.1 | 22.7 | 50 | 34.0 | 21.7 | − 0.09 (− 0.49 to 0.30) |
Trial | 96 | 31.4 | 22.8 | 96 | 22.7 | 18.4 | − 0.42 (− 0.70 to − 0.13) |
HADS (depression) | |||||||
Beacon Sites | 23 | 6.4 | 5.0 | 23 | 5.7 | 4.2 | − 0.15 (− 0.73 to 0.43) |
Trial | 95 | 4.2 | 3.3 | 95 | 3.6 | 2.7 | − 0.20 (− 0.48 to 0.09) |
HADS (anxiety) | |||||||
Beacon Sites | 23 | 7.2 | 5.2 | 23 | 6.5 | 4.4 | − 0.14 (− 0.72 to 0.44) |
Trial | 95 | 4.7 | 4.2 | 95 | 4.4 | 3.9 | − 0.07 (− 0.36 to 0.21) |
ISWT (m) | |||||||
Beacon Sites | 13 | 190.0 | 119.4 | 13 | 211.5 | 122.9 | 0.17 (− 0.60 to 0.94) |
Trial | 84 | 277.8 | 152.5 | 84 | 322.3 | 173.2 | 0.27 (− 0.03 to 0.58) |